Summary:
The purpose of this study is to compare the effectiveness, safety, and tolerability of upadacitinib to placebo (fake drug without any active substance) on reduction of signs
and symptoms for subjects with axial spondyloarthritis
Qualified Participants Must:
• Be 18 years of age or older
•
Be diagnosed with (ankylosing spondylitis [AS] or non-radiographic axial spondyloarthritis [nr-axSpA])
•
Have not responded sufficiently to at least 2 NSAIDs or cannot take NSAIDs due to side effects and/or who have been treated with a biologic therapy (for example, adalimumab, etanercept, infliximab, tocilizumab, abatacept, secukinumab, ixekizumab)
Qualified Participants May Receive:
Study-related medication, care, and labs at no cost
Compensation for time and travel for each completed study visit